Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Alginate Chewable Tablets for Gastro-Oesophageal Reflux Disease
2014-005261-69Phase 3Completed
- Sponsor
- Reckitt
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Gaviscon Double Action in gastroesophageal reflux disease (GERD), sponsored by Reckitt. Started Apr 2015; status: completed.
02
Drugs
Gaviscon Double Action
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2014-005261-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005261-69.